Long-Term Use of This Contraceptive Pill Linked to Increased Brain Tumor Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Using the progestogen-only contractive pill "desogestrel" for more than five years may increase the risk of developing a type of brain tumor known as an "intracranial meningioma," a new study has warned.
The researchers noted that the risk is low—and is eliminated one year after desogestrel treatment is suspended—but that doctors' awareness of the possibility could eliminate the need for surgery in some cases.
Meningiomas are a rare, non-cancerous form of tumor that arise from the membranes surrounding the brain. While slow-growing and benign in and of themselves, they can develop to a size that compresses other structures in the brain.
They usually only require surgery when they cause symptoms such as persistent headaches or neurological issues.
Woman holding combined oral contraceptive pill.
Woman holding combined oral contraceptive pill.
PATCHARIN SIMALHEK
The study, based on data from France's national health system, compared over 8,000 women who underwent surgery for meningioma between 2020 and 2023 with more than 83,000 matched controls.
Researchers found that women who had taken desogestrel continuously for more than five years had a slightly elevated risk of developing the brain tumors.
Reassuringly, no increased risk was found for short-term use or for other commonly used progestogens like levonorgestrel, either alone or combined with estrogen.
"This large study using French national database... shows [an] association between taking a certain progestogen (desogestrel) continuously for more than five years and meningioma risk, however, the magnitude of increase in the risk is small," said paper author Dr. Mangesh Thorat of Queen Mary University of London in a statement.
Short-term use does not increase risk and the risk ceases after stopping use, he added.
The authors estimate that one woman in every 67,000 using desogestrel would need surgery for meningioma and this drops to 1 in 17,000 with continuous use beyond five years.
By comparison, breast cancer is about 10 times more common than meningioma.
To understand progestogens, Thorat said it's crucial to note that the effects of different drug formulations can vary significantly and individual drugs can affect various organs differently.
"Therefore, it is important to consider which specific drug is being used by an individual," he said.
The study also showed that Microgynon and the morning-after pill—both containing levonorgestrel—were not linked to increased risk.
Still, the findings have clinical relevance, especially for women over 45 or those with a prior history of using other high-risk progestogens.
In such cases, the study suggests discontinuing desogestrel if a meningioma is identified, rather than jumping straight to surgery.
"Stopping desogestrel may also avoid unnecessary potentially harmful treatments," said neurosurgeon Gilles Reuter of the University Hospital Liegein an accompanying editorial.
Reuter emphasized that similar results have already been seen with other high-risk progestogens.
While the study is observational and cannot prove cause and effect, its large sample size adds weight to the findings. However, experts say the takeaway should be caution, not alarm.
For those affected by the findings, Thorat advises speaking with a healthcare provider regarding which drug is being used.
"If it is associated with an increased risk of meningioma, this can be changed to a safer alternative," he said.
"There is no reason to panic as the risk is very small and even in those who developed meningioma, stopping the specific drug has shown to cause regression in the size of meningioma."
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about contraceptives? Let us know via health@newsweek.com.
References
Roland, N., Kolla, E., Baricault, B., Dayani, P., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2025). Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: National case-control study. BMJ, 389. https://doi.org/10.1136/bmj-2024-083981
Reuter, G. (2025). Progestogens and meningioma: New evidence on levonorgestrel and desogestrel. BMJ, 389. https://doi.org/10.1136/bmj.r1095
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Dried Fruit Recall Map Shows 19 States With New Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Turkana Food Inc. has issued a recall for their dried apricots because the package label does not disclose that the product contains sulfites. Newsweek reached out to the company via phone Thursday and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. What To Know According to the FDA alert, the Floria brand dried apricots have an expiration date of November 2026. The impacted product has a LOT number of 440090478-15-333 that can be found at the bottom of the packaging. The product has a UPC Label of 2539560010 that can be seen on a sticker at the top of the package, the FDA says. The dried apricots were distributed in Florida, Kentucky, Virginia, New York, New Jersey, Tennessee, Massachusetts, Texas, Illinois, Indiana, Michigan, Rhode Island, Pennsylvania, North Carolina, Maryland, Ohio, Alabama, Missouri and California. There have been no reported illnesses as of Thursday, the FDA says. The alert also has pictures of the recalled product that potential customers can cross reference. Below is a map of the impacted states: What People Are Saying The FDA alert in part: "The recall was the result of a routine sampling performed by the New York State Department of Agriculture and markets which revealed that the finished products contained Sulfites that were not listed on the product labelling. The company has ceased production and distribution of the products as FDA and the company continue their investigation to correct the issue with the manufacturer." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled dried apricots are asked not to eat them and return them to the original place of purchase for a refund, the FDA says. People with additional questions may call Turkana Foods Inc. at 908-810-8800 on weekdays from 8 a.m. to 6 p.m. ET.
Newsweek
3 hours ago
- Newsweek
Bernie Sanders Introduces Bill Backing RFK Jr., Elon Musk Priority
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Senator Bernie Sanders is leading a new bill to address a key priority of Robert F. Kennedy Jr., who serves as President Donald Trump's Health and Human Services Secretary. Why It Matters Sanders, a Vermont independent, alongside Senator Angus King, a Maine independent, introduced the "End Prescription Drug Ads Now Act," which, if passed, would ban prescription drug advertising on TV, radio, print and digital platforms as well as social media. Critics say these ads contribute to the high price of healthcare while doing little to improve care in the United States, though proponents say the advertisements can improve patients' knowledge of healthcare. Most wealthy countries, with the U.S. and New Zealand being two notable exceptions, ban pharmaceutical drug advertisements. The bill also represents an issue where Sanders, viewed as perhaps the most progressive senator, has found common ground with Kennedy inside the Trump administration, though the secretary has not commented on this bill specifically. What to Know Sanders and King announced the legislation on Thursday, highlighting that the pharmaceutical industry spent more than $5 billion on TV ads in 2024 and that many of these drugs cost more in the U.S. than in other countries that do not allow drug companies to run ads on TV. "The American people are sick and tired of greedy pharmaceutical companies spending billions of dollars on absurd TV commercials pushing their outrageously expensive prescription drugs," Sanders said, describing the fact that the U.S. stands mostly alone in allowing pharmaceutical ads as an "international embarrassment." vSenator Bernie Sanders, a Vermont independent, questions U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. during a committee hearing on May 14, 2025 in Washington, D.C. vSenator Bernie Sanders, a Vermont independent, questions U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. during a committee hearing on May 14, 2025 in Washington, director of communications Anna Bahr confirmed to Newsweek his office has reached out to Republicans to join the bill. Bahr pointed to lobbying from the pharmaceutical and health insurance industries as to why the U.S. has not joined other countries in bannign the ads. "Over the past 25 years, the drug companies have spent $8.5 billion on lobbying. Today, they have some 1,800 well-paid lobbyists in Washington, D.C. – including former leaders of the Republican and Democratic parties," she said in a statement to Newsweek. "Unbelievably, that is more than three lobbyists for every member of Congress. During that same period, they have provided over $700 million in campaign contributions. And they are equal opportunity contributors. They contribute heavily to both Republican and Democratic candidates." Secretary Kennedy—as well as Elon Musk, who previously served in Trump's administration—have expressed support for ending pharmaceutical advertising. "Let's get President Trump back in the White House and me to DC so we can ban pharmaceutical advertising," Kennedy wrote in a post to X (formerly Twitter) on November 3, 2024. During his own presidential campaign, Kennedy said he would have issued an executive order ending the advertisements on his first day in office. Newsweek reached out to DHS for comment via the department's press contact form. Caleb Alexander, professor of epidemiology at the Johns Hopkins University Bloomberg School of Public Health, told Newsweek that while a potential ban's impact on drug prices remains uunclear, there would be benefits to ending these advertisements. Pharmaceutical advertisements can drive up "inappropriate demand" for prescription drugs in settings where they may not be needed, he said. "In terms of the potential benefits of banning [direct-to-consumer advertisements], the most immediate and likely is that it would temper demand for products in settings where they may not be needed," Alexander said. The U.S. has "evolved to believe" the benefits of the ads, such as empowering patients to identify health concerns, outweigh the risks, though much of the research on the topic indicates that the benefits may not be worth the drawbacks, he said. What People Are Saying Alexander told Newsweek: "Direct to consumer advertising has been a lightning rod for controversy, and it remains a curious and unique feature of the U.S. marketplace. While a ban on direct advertising may be welcomed by many, it's not going to fundamentally transform the marketplace for prescription drugs in the United States, simply because DTCA is highly concentrated among a small number of products. It may be a reasonable political and public health target, but I think that if you just look at the way the dollars flow, there's vastly more money spent on marketing drugs to prescribers." Senator Angus King wrote in a statement: "The widespread use of direct-to-consumer advertising by pharmaceutical companies drives up costs and doesn't necessarily make patients healthier. The End Prescription Drug Ads Now Act would prohibit direct-to-consumer advertising of pharmaceutical drugs to protect people. This bill is a great step to ensure that patients are getting the best information possible and from the right source: their providers and not biased advertisements." Elon Musk wrote to X in November 2024: "No advertising for pharma." What Happens Next It's unclear whether a majority of senators are also in support of the bill. So far, Democratic Senators Chris Murphy of Connecticut, Peter Welch of Vermont, Jeff Merkley of Oregon and Dick Durbin of Illinois have co-sponsored the bill, according to Sanders' office.
CBS News
4 hours ago
- CBS News
Underwater military drone accidentally stumbles upon deepest shipwreck ever found off France: "As if time froze"
What technology could change the way we learn about shipwrecks What technology could change the way we learn about shipwrecks What technology could change the way we learn about shipwrecks Archaeologists have discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France, the deepest such find in its section of the Mediterranean or any other French waters. Archaeologists believe the ship was sailing from northern Italy loaded with ceramics and metal bars before it sunk. Despite a little modern waste dotting its sunken cargo at 8,422 feet below sea level, researchers were excited about the potential of an archaeological site largely preserved intact. "It's the deepest shipwreck ever found in French territorial waters," Arnaud Schaumasse, the head of the culture ministry's underwater archaeology department, said late Wednesday. France's Department of Underwater and Submarine Archaeological Research released images of the shipwreck on social media, saying the vessel was discovered "during a military operation to explore the seabed." Archaeologists say they discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France. National Navy via France's Department of Underwater and Submarine Archaeological Research An underwater drone stumbled upon the sunken ship by chance in early March in waters near Saint-Tropez in southeastern France, deputy maritime prefect Thierry de la Burgade said. "The sonar detected something quite big, so we went back with the device's camera, then against with an underwater robot to snap high-quality images," he said. The drone was patrolling the seabed as part of a government project to explore and monitor France's deep-sea resources, from minerals to deep-sea internet cables. Archaeologist Marine Sadania said experts discovered 200 jugs with pinched spouts among the wreckage at the site they have dubbed "Camarat 4." Some of these jugs were marked with the monogram "HIS," the first three letters of the Greek name of Jesus, or covered with plant-inspired or geometric patterns. Those details seemed to indicate the jugs hailed from the Liguria region in what is now northern Italy, she said. "Camarat 4 is a remarkable discovery for its depth, unprecedented character and the opportunity it offers to study an almost intact 16th-century wreck," France's Department of Underwater and Submarine Archaeological Research said. "As if time froze" Experts also identified piles of around 100 yellow plates, two cauldrons, an anchor and six cannons. Modern waste, such as a soda can or an empty yogurt container, were spotted too. One image released by officials appeared to show an aluminum can next to an anchor. Archaeologists say they discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France. National Navy via France's Department of Underwater and Submarine Archaeological Research But despite this, "the site -- thanks to its depth which prevented any recovery or looting -- has remained intact, as if time froze, which is exceptional," Sadania said. Over the coming two years, she and colleagues plan to draw up a 3D digital version of the ship, as well as extract samples from the site to better study them before returning them to the public domain. According to the defense ministry in charge of exploring France's deep seas, researchers can remove an item from a shipwreck by guiding a submarine robot with pincers or arms, via a long cable linking the device to a boat on the surface. Officials said further analysis will be carried out by ceramic experts, archaeologists and specialists in naval architecture. The deepest French authorities had found a sunken vessel until now was 2.3 kilometers under sea level off the southern city of Toulon in 2019. The wreckage belonged to La Minerve, a French submarine that plunged to its demise in 1968 with 52 navy crew on board, only four minutes after the start of a routine assignment.
